摘要目的:了解宁波市2022年新报告HIV-1感染者毒株基因型特征和原发耐药情况。方法:收集2022年1—12月宁波市新报告HIV-1感染者ART治疗前血浆，提取RNA，反转录后巢氏PCR扩增HIV-1 pol基因片段，系统进化分析鉴定基因亚型，同时提交序列至斯坦福大学耐药数据库进行耐药分析。 结果:2022年宁波市新报告HIV-1感染者628例，成功获得426例序列，共检出15种基因亚型。CRF07_BC（42.0%，179/426）和CRF01_AE（30.5%，130/426)为两个优势基因亚型，随后依次为独特重组型（unique recombinant form，URF）(01_AE/07_BC) (7.0%，30/426)、CRF 08_BC（6.6%，28/426)、CRF 55_01B（4.9%，21/426)、CRF85_BC（2.3%，10/426）、B (2.1%，9/426)、C（1.9%，8/426)、URF(B/C) (0.7%，3/426)、URF (01_AE/C)（0.5%，2/426）、URF (01_AE/B)（0.5%，2/426）、CRF59_01B（0.2%，1/426）、CRF64_BC（0.2%，1/426）、CRF67_B（0.2%，1/426）和A1（0.2%，1/426）。治疗前耐药率为6.3%(27/426)，其中非核苷类逆转录酶抑制剂、核苷类逆转录酶抑制剂和蛋白酶抑制剂耐药率分别为3.8%(16/426)、1.9%(8/426)和0.9%(4/426)。结论:2022年宁波市新报告HIV-1感染者毒株亚型复杂多样，有较高比例URF，治疗前处于中度耐药。

abstractsObjective:To understand the characteristics of HIV-1 genotypes and primary drug resistance among newly reported HIV-1 infected people in Ningbo in 2022.Methods:Plasma samples were collected from newly reported HIV-1 infected patients before ART in Ningbo from January to December 2022. RNA was extracted, RT-PCR and nested PCR were used to amplify the pol gene sequences of HIV-1 strains. The genotypes were identified by phylogenetic tree construction. Drug resistance of these strains were analyzed by the online tool of the Stanford University HIV-1 Drug Resistance Database. Results:A total of 628 HIV-1 infected people were newly reported in Ningbo in 2022, of which 426 sequences were successfully obtained, revealing 15 different genotypes. The two predominant subtypes were CRF07_BC (42.0%, 179/426) and CRF01_AE (30.5%, 130/426), followed by unique recombinant form(URF)(01_AE/07_BC) (7.0%, 30/426), CRF08_BC (6.6%, 28/426), CRF55_01B (4.9%, 21/426), CRF85_BC (2.3%, 10/426), B (2.1%, 9/426), C (1.9%, 8/426), URF(B/C) (0.7%, 3/426), URF(01_AE/C) (0.5%, 2/426), URF(01_AE/B) (0.5%, 2/426), CRF59_01B (0.2%, 1/426), CRF64_BC (0.2%, 1/426), CRF67_B (0.2%, 1/426), and A1 (0.2%, 1/426). The overall primary drug resistance rate was 6.3% (27/426), with resistance rates to non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors of 3.8% (16/426), 1.9% (8/426), and 0.9% (4/426), respectively.Conclusions:HIV-1 genotypes of newly reported HIV-1 infected people in Ningbo in 2022 are diverse, including a relatively high proportion of URFs. The overall drug resistance rate of patients before ART is intermediate.